Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 5/2007

01-03-2007 | Case Report

A novel therapeutic option in Cogan diseases? TNF-α blockers

Authors: M. Fricker, A. Baumann, F. Wermelinger, P. M. Villiger, A. Helbling

Published in: Rheumatology International | Issue 5/2007

Login to get access

Abstract

Cogan’s syndrome is characterized by non-infectious, interstitial keratitis combined with a vestibulo-auditory deficit. Despite therapy with corticosteroids in combination with immunosuppressive agents, relapses occurred in two subjects and the clinical course suggested a progression of the disease. Treatment with anti-TNF-α was started leading to a rapid and sustained clinical remission for over 2 respectively 3 years.
Literature
1.
Cogan DG (1945) Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthalmol 33:144
2.
Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS (1980) Cogan syndrome: studies in thirteen patients, long-term follow up, a review of the literature. Medicine (Baltimore) 59:426–439
3.
Vollertsen RS, McDonald TJ, Younge BR, Banks BM, Stanson AW, Ilstrup DM (1986) Cogan’s syndrome: 18 cases and a review of the literature. Mayo Clin Proc 61:344–361PubMed
4.
Allen NB, Cox CC, Cobo M, Kisslo J, Jacobs MR, Mc Callum RM, Haynes BF (1990) Use of immunosuppressive agents in the treatment of the severe ocular and vascular manifestations of Cogan’s syndrome. Am J Med 88:296–301PubMedCrossRef
5.
Baumann A, Helbling A, Oertle S, Häusler R, Vibert D (2005) Cogan’s syndrome: clinical evolution of deafness and vertigo in three patients. Otology 262:45–49
6.
Lundardi C, Bason C, Leandri M, Navone R, Lestani M, Millo E et al (2002) Autoantibodies to inner ear and endothelial antigens in Cogan’s syndrome. Lancet 360:915–921CrossRef
7.
Arnold W, Gebbers JO (1984) Serum-Antikörper gegen Kornea und Innenohrgewebe beim Cogan-Syndrom. Laryngol Rhinol Otol 63:428–432CrossRef
8.
Helmchen C, Arbusow V, Jäger L, Strupp M, Stöcker W, Schulz P (1999) Cogan’s syndrome: clinical significance of antibodies against the inner ear and cornea. Acta Otolaryngol 119:528–537PubMedCrossRef
9.
St. Clair EW, McCallum RM (1999) Cogan’s syndrome. Curr Opin Rheumatolog 11:47–52CrossRef
10.
Matteson EL, Tirzaman O, Facer GW, Fabry DA, Kaperbauer J, Beatty CW, McDonald TJ (2000) Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 109:710–714PubMed
11.
Riente L, Taglione E, Berrettini S (1996) Efficacy of methotrexate in Cogan’s syndrome. J Rheumatol 23:1830–1831PubMed
12.
Kasapcopur OE, Ashraf M, Caliskan S, Arisoy N (2000) Cogan’s syndrome: a rare vasculitis in childhood. J Rheumatol 27:1824–1825PubMed
13.
Lipsky PE et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumour necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602PubMedCrossRef
14.
Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM (2002) Inhibition of the TNF-pathway use of infliximab an etanercept as remission-inducing agents in cases of therapy resistant chronic inflammatory disorders. Swiss Med Wkly 132(29–30):414–422PubMed
Metadata
Title
A novel therapeutic option in Cogan diseases? TNF-α blockers
Authors
M. Fricker
A. Baumann
F. Wermelinger
P. M. Villiger
A. Helbling
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0252-y

Other articles of this Issue 5/2007

Rheumatology International 5/2007 Go to the issue

Original Article

Skin damage occurs early in systemic lupus erythematosus and independently of disease duration in Brazilian patients

Original Article

Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus

Case Report

Autoimmune hepatitis with raised alpha-fetoprotein level as the presenting symptoms of systemic lupus erythematosus: a case report

Original Article

Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)

Original Article

Pregnancy outcome in idiopathic inflammatory myopathy

Review

Immunopathogenesis of Behçet’s disease with special emphasize on the possible role of antigen presenting cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits